Objective:

To discuss the urgent need to address the limitations of current diagnostic approaches for chronic diseases and explore the potential of biology-driven diagnostics.

Key Findings:

• Current diagnostics often rely on late-stage signals, leading to reactive care.
• There is a critical need for reliable biomarkers that can detect early and pre-disease states.
• Many diagnostics indicate abnormalities without clarifying risk or next steps, complicating patient management.
• Improved diagnostics can reduce unnecessary procedures and enhance patient-centered care.
• Clinically actionable diagnostics must deliver reproducible and practical results within routine workflows, directly impacting treatment decisions.

Interpretation:

Advancements in biomarkers and proteomics are essential for improving diagnostic precision and patient management in chronic diseases, ultimately leading to better health outcomes.

Limitations:

• Current diagnostics struggle to distinguish clinically meaningful disease from benign findings, which can lead to mismanagement.
• Many existing tools lack specificity and are not directly linked to disease biology, resulting in potential misdiagnosis.
• Validated disease-modifying biomarkers are lacking in CNS diseases, hindering effective treatment strategies.

Conclusion:

The future of diagnostics in chronic disease management lies in developing precise, actionable tools that enhance early detection and treatment decision-making, with a strong emphasis on integrating AI technologies.